Genomic Valley Biotech Ltd (539206)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Genomic Valley's revenue was ₹0.0 Cr (-57.8% year on year, -5.0% on the previous quarter), and net profit ₹0.0 Cr (-26.9% year on year); the operating margin was 40.6%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹0.0 | -57.8% | -5.0% |
| Operating profit | ₹0.0 | -48.6% | — |
| Net profit | ₹0.0 | -26.9% | from loss |
| EPS (₹) | 0.05 | -28.6% | from loss |
| Operating margin | 40.6% | — | — |
📢 Recent Corporate Announcements
Genomic Valley Biotech Limited has received approval from the Registrar of Companies (ROC), Haryana, granting a 3-month extension to conduct its Annual General Meeting (AGM) for the financial year ended March 31, 2026. The AGM, which was originally due on or before September 30, 2026, can now be held up to December 31, 2026. The extension was sought citing health reasons of the promoter. The company noted that the exact date of the AGM will be intimated in due course once decided by the Board.
- ROC Haryana approved a 3-month extension for holding the FY26 AGM via letter dated August 30, 2026
- AGM deadline extended from September 30, 2026, up to December 31, 2026
- Application was filed under Section 96(1) of the Companies Act, 2013 on August 26, 2026, citing promoter health reasons
- Board will intimate the revised AGM schedule and book closure dates in due course
Genomic Valley Biotech approved its standalone unaudited financial results for the quarter ended June 30, 2026. The company registered revenue of ₹0.038 crore, down from ₹0.09 crore in the corresponding quarter of the previous year. Net profit stood at ₹0.015 crore (EPS of ₹0.05), recovering from a net loss of ₹0.01 crore in the previous quarter (Q4 FY26). The statutory auditors issued an unmodified limited review report.
- Standalone quarterly revenue reported at ₹0.038 crore for the quarter ended June 30, 2026.
- Net profit recorded at ₹0.0146 crore with an EPS of ₹0.05.
- Board meeting concluded in 40 minutes (03:00 PM to 03:40 PM on August 14, 2026).
- Statutory auditor ANDROS & CO issued a clean/unmodified Limited Review Report.
Genomic Valley Biotech Ltd has approved its standalone un-audited financial results for the quarter ended June 30, 2026. The company is a micro-cap with a market capitalization of only ‑8 Cr and has seen a significant decline in annual revenue from ‑0.84 Cr in FY25 to ‑0.27 Cr in FY26. Recent quarterly performance shows revenue stagnating between ‑0.04 Cr and ‑0.09 Cr. The board meeting was brief, lasting 40 minutes, and the statutory auditors provided a standard limited review report without qualifications.
- Board approved standalone un-audited financial results for the quarter ended June 30, 2026
- Company revenue has declined significantly from ‑0.84 Cr in FY25 to ‑0.27 Cr in FY26
- Market capitalization remains extremely low at ‑8 Cr with a high P/E ratio of 414.4
- The board meeting commenced at 03:00 P.M. and concluded at 03:40 P.M. on August 14, 2026
- Promoter holding has remained stable at 46.06% as of June 2026
Genomic Valley Biotech Ltd (Market Cap: Rs 8 Cr) has scheduled a board meeting for August 14, 2026, to approve its unaudited standalone results for the quarter ended June 30, 2026. The company is currently operating on a very small scale, with FY26 revenue falling to Rs 0.27 Cr from Rs 0.84 Cr in FY25. The trading window for insiders has been closed since July 01, 2026, and will reopen 48 hours after the results are made public. Given the high P/E ratio of 414.3 and negligible revenue, the upcoming results are critical for assessing the company's operational viability.
- Board meeting scheduled for August 14, 2026, to consider Q1 FY27 results
- Trading window closed from July 01, 2026, until 48 hours after the results are public
- Company reported a low revenue of Rs 0.27 Cr for the full year FY26
- Market capitalization is approximately Rs 8 Cr with a high P/E of 414.3
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
